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Original ArticleFGF21, a liver hormone that inhibits alcohol
intake in mice, increases in human circulation
after acute alcohol ingestion and sustained
binge drinking at OktoberfestSusanna Søberg 1,2,5, Emilie S. Andersen 3,4,5, Niels B. Dalsgaard 3, Ida Jarlhelt 1, Nina L. Hansen 3,
Nina Hoffmann 3, Tina Vilsbøll 3,4, Anne Chenchar 1, Michal Jensen 2, Trisha J. Grevengoed 1,
Sam A.J. Trammell 1, Filip K. Knop 1,3,4,**,5, Matthew P. Gillum 1,*,5ABSTRACT
Objective: Excessive alcohol consumption is a leading cause of global morbidity and mortality. However, knowledge of the biological factors that
inﬂuence ad libitum alcohol intake may be incomplete. Two large studies recently linked variants in the KLB locus with levels of alcohol intake in
humans. KLB encodes b-klotho, co-receptor for the liver-derived hormone ﬁbroblast growth factor 21 (FGF21). Inmice, FGF21 reduces alcohol intake,
and human Fgf21 variants are enriched among heavy drinkers. Thus, the liver may limit alcohol consumption by secreting FGF21. However, whether
full-length, active plasma FGF21 (FGF21 (1e181)) levels in humans increase acutely or sub-chronically in response to alcohol ingestion is uncertain.
Methods: We recruited 10 healthy, fasted male subjects to receive an oral water or alcohol bolus with concurrent blood sampling for FGF21 (1e
181) measurement in plasma. In addition, we measured circulating FGF21 (1e181) levels, liver stiffness, triglyceride, and other metabolic
parameters in three healthy Danish men before and after consuming an average of 22.6 beers/person/day (4.4 g/kg/day of ethanol) for three days
during Oktoberfest 2017 in Munich, Germany. We further correlated fasting FGF21 (1e181) levels in 49 healthy, non-alcoholic subjects of mixed
sex with self-reports of alcohol-related behaviors, emotional responses, and problems. Finally, we characterized the effect of recombinant human
FGF21 injection on ad libitum alcohol intake in mice.
Results: We show that alcohol ingestion (25.3 g orw2.5 standard drinks) acutely increases plasma levels of FGF21 (1e181) 3.4-fold in fasting
humans. We also ﬁnd that binge drinking for three days at Oktoberfest is associated with a 2.1-fold increase in baseline FGF21 (1e181) levels, in
contrast to minor deteriorations in metabolic and hepatic biomarkers. However, basal FGF21 (1e181) levels were not correlated with differences
in alcohol-related behaviors, emotional responses, or problems in our non-alcoholic subjects. Finally, we show that once-daily injection of re-
combinant human FGF21 reduces ad libitum alcohol intake by 21% in mice.
Conclusions: FGF21 (1e181) is markedly increased in circulation by both acute and sub-chronic alcohol intake in humans, and reduces alcohol
intake in mice. These observations are consistent with a role for FGF21 as an endocrine inhibitor of alcohol appetite in humans.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Alcohol abuse is implicated in more than 2.3 million deaths worldwide
every year, and is the ninth largest contributor to the global burden of
disease in terms of disability-adjusted life years (DALYs) [1]. Moreover,
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of these problems [2]. However, drugs that adequately control alcohol
use disorders have yet to be developed, in part because the biology
that motivates alcohol consumption is incompletely understood [3].
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non-alcoholic subjects [p ¼ 9.2  1012] [4]. This result was repli-
cated in an additional 112,117 subjects from the UK Biobank that also
linked rs11940694 [p ¼ 8.4  1019] as well as rs9991733
[p ¼ 3.80  109] in KLB with alcohol drinking in humans [5]. The
KLB gene encodes b-klotho, an essential co-receptor in vivo for the
metabolic hormones FGF19 and FGF21 [6].
Circulating FGF21 is mainly derived from the liver and is best known for
its beneﬁcial effects on glucose, lipids, and body weight when given
pharmacologically to rodents [7,8]. In humans, FGF21 has limited ef-
fects on glycemia, but does improve lipid homeostasis and weight,
suggesting that some, but not all, of its rodent functions may be
conserved [9,10]. In mice, alcohol increases circulating FGF21 levels
[11,12] and FGF21 overexpression or continuous infusion by minipump
reduces alcohol and sweet intake via a b-klotho-dependent cascade in
the central nervous system [4,13]. In addition, a bispeciﬁc antibody that
activates the b-klotho/FGFR1 complex reduces alcohol and saccharin
intake in mice [14]. In favor of a conserved role for FGF21 as a negative
regulator of alcohol and sugar intake in humans, the Fgf21 rs838133 A-
allele is enriched among the top tertile of alcohol drinkers and sweet
consumers in the Danish Inter99 cohort [15]. Moreover, it was recently
reported that oral ethanol markedly increases circulating total FGF21
levels in humans [16]. Together, these observations suggest that alcohol
ingestion increases hepatic secretion of FGF21, which then acts via the
b-klotho/FGFR1 complex to suppress further alcohol intake.
To test this prediction, we assessed plasma FGF21 (1e181) levels in
fasted humans after acute and sub-chronic alcohol ingestion and
measured the effects of bolus human FGF21 administration on alcohol
preference in mice. We further correlated fasting FGF21 (1e181)
levels with self-reported alcohol-related behaviors, emotional re-
sponses, and problems in a cohort of 49 healthy human subjects.
2. MATERIALS AND METHODS
2.1. Subjects for the acute and questionnaire alcohol studies
Male subjects age 18e30 years, with a body mass index (BMI) of 19e
25 kg/m2 and without any medical conditions were recruited for
participation by advertisement. Individuals with chronic diseases, his-
tory of alcohol abuse, and current or former smoking were excluded.
Additionally, individuals who were on a diet, were taking dietary sup-
plements, had a history of eating disorders, recently experienced weight
loss (>3 kg within 3 months), or used daily medications were excluded
from participation. The study was approved by the Scientiﬁc Ethics
Committee of the Capital Region of Denmark (H-16038581). All subjects
provided written and informed consent prior to participation in the study,
which was performed in accordance with the principles enumerated in
the Declaration of Helsinki II.
The 10 subjects selected for the acute alcohol (ethanol) study un-
derwent a pre-examination that included baseline laboratory tests
(after a 12 h overnight fast), medical history, and physical examination.
A 2-h oral glucose tolerance test (OGTT) was performed to conﬁrm that
none of the subjects had impaired glucose tolerance (9e11 mmol/l
after two hours) or were insulin resistant (plasma insulin levels above
normal: 10e125 pmol/l). Subjects were instructed to refrain from
alcohol and caffeine intake 48 h prior to participation in the study and
none of the subjects had any signiﬁcant alcohol drinking at least one
week prior to the study day.
Recruitment of subjects for the alcohol questionnaire cohort and oral
sucrose challenge (whose baseline FGF21 levels were correlated with
responses to the Alcohol Use Disorder Test (AUDIT) and Alcohol Use
Disorders Identiﬁcation Test-E (ALCOHOL-E), combined with those of
subjects from the ethanol study) has been described elsewhere [15]. InMOLECULAR METABOLISM 11 (2018) 96e103  2018 The Authors. Published by Elsevier GmbH. This is an open a
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healthy subjects of mixed sex, answered the alcohol questionnaires
that were sent by e-mail. Subjects were advised to sit alone while
answering the questionnaires, not be under the inﬂuence of alcohol,
and to answer as honestly as possible with the understanding that their
responses were anonymous.
2.2. Oktoberfest cases
Three healthy Danish men (aged 42 years, BMIs of 23.8, 21.4, 28.3 kg/
m2) with moderate, social drinking habits contacted our clinic for a
health examination before three days of Oktoberfest participation in
Munich, Germany. Upon their return they asked for a reevaluation of
their metabolic health (32 h after consuming the last unit of alcohol at
Oktoberfest). All agreed to have their cases reported anonymously.
2.3. Acute alcohol study
On the study day, subjects in the acute ethanol cohort met after an
overnight fast (12 h) and 48 h abstention from physical activity and
caffeine intake. Furthermore, subjects were instructed not to consume
alcohol one week prior to the study day. Blood samples were collected
in the fasting state from an antecubital vein at 10 and 0 min and 15,
30, 60, 90, 120, 180, and 240 min after ingestion of 280 ml of either
tap water or ethanol mixed with tap water (8 cL of 40% ethanol in
200 ml tap water). Subjects were randomized to either the water
control group or the alcohol group using a computer randomization
system at www.easytrial.net. During the study day the subjects were
resting in a hospital bed and instructed to relax but not sleep.
2.4. Oktoberfest case examinations
Subjects were examined in the morning after an overnight (10 h) fast.
Body weight, height, body composition (by bioimpedance), and hepatic
stiffness (by ﬁbroscanning) were evaluated, and blood and urine were
sampled. Insulin resistance was measured by the homeostatic model
assessment (HOMA-IR) and homeostatic model assessment 2 (HOMA-
2IR) with the HOMA2-IR being a computerized model recalibrated to
the modern insulin assays. HOMA-IR is calculated using the fasting
plasma glucose and the fasting insulin levels divided by 22.5 (HOMA-
IR ¼ [FPG  FPI]/22.5).
2.5. Alcohol questionnaires
Subjects in the acute ethanol cohort (n ¼ 10) and the sweet-liking
cohort (n ¼ 39) answered two questionnaires concerning their
alcohol habits. One of the questionnaires, AUDIT, is a validated
questionnaire, used to identify patients at risk of alcohol-related health
problems or alcohol dependence. The questionnaire consists of 10
questions divided into three categories; Alcohol intake, Alcohol
dependence, and Harmful alcohol use. The score for all 10 questions is
aggregated and the total AUDIT score can range from 0 to 40. The
score is interpreted as follows: a score of 7 indicates an alcohol
problem; a score of 8e15 indicates a large amount of consumption
that can be remedied by short intervention; a score of 16e19 suggests
harmful consumption, which requires short intervention and/or medical
treatment; a score of 20 strongly suggests addiction, but addiction
cannot be excluded if the score is below this limit.
The second alcohol-questionnaire, “Alcohol-E” (Alcohol Use Disorders
Identiﬁcation Test-E), was originally developed in Sweden to identify
alcohol use disorders. In this study, we used the Danish version of
Alcohol-E. Alcohol-E provides a structured view of a person’s alcohol
use. The questionnaire consists of 4 sections with the following ques-
tions: 1. How often do you have the following alcoholic drinks? (e.g.
beer, strong beer, wine and alcoholic soda-drinks); 2. What is positiveccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 97
Table 1 e Subject characteristics.
Alcohol (n ¼ 5) Water (n ¼ 5) p value
Age (years) 24 (4.9) 27 (1.5) 0.26
Body mass index (BMI) (kg/m) 23.4 (1.6) 24.4 (1.6) 0.39
Waist circumference (cm) 84.2 (5.6) 83.3 (6.6) 0.84
Fasting plasma glucose (mmol/l) 4.5 (0.2) 4.5 (0.3) 0.31
Fasting plasma insulin (pmol/l) 42.6 (16.8) 21.8 (8.0) 0.18
Fasting plasma FGF21 (1e181)
(pg/ml)
173.6 (209.8) 155 (90.6) 0.86
HbA1c (CDDT%) 5.2 (1.7) 5.3 (0.7) 0.87
Hemoglobin (mmol/l) 9.2 (0.4) 8.6 (0.4) 0.42
Total cholesterol (mmol/l) 4.6 (0.9) 4.1 (0.5) 0.29
HDL cholesterol (mmol/l) 1.3 (0.2) 1.3 (0.2) 0.94
LDL cholesterol (mmol/l) 3.1 (0.8) 2.6 (0.8) 0.99
Triglycerides (pmol/l) 0.8 (0.2) 0.7 (0.3) 0.7
C-reactive protein (mmol/l) 0.2 (0.8) 0.1 (0.2) 0.12
ALAT (U/l) 23 (5.6) 32.8 (0.3) 0.15
ASAT (U/l) 25 (7.5) 35.4 (13.9) 0.18
Thyrotropin (mU/l) 1.6 (0.7) 2.3 (1.2) 0.38
Triiodothyronine (T3) (pmol/l) 5.5 (0.8) 5.3 (0.66) 0.66
Thyroxine (T4) (pmol/l) 16.5 (2.1) 16.8 (2.4) 0.8
Data are expressed as mean  SD.
Original Articlefor youwhen using alcohol? (e.g. sleep better, get happy, feel strong and
getting better at contacting other people); 3. What is negative for you
when using alcohol? (e.g. become anxious, have suicidal thoughts, have
less contact with friends, experience low libido); 4. What do you think
about alcohol? (e.g. do you enjoy drinking alcohol, do you feel it is
important to change your alcohol use, and have you the past year been
concerned about your alcohol use?). In this study, we used the “Alcohol-
E” questionnaire to get a deeper insight into which alcoholic drinks our
subjects preferred and to achieve more knowledge on the negative and
positive effects of their drinking habits. The results from the question-
naire were calculated by dividing the mean score for each section by the
number of questions in that section.
2.6. FGF21 measurements
Blood samples used for FGF21 (1e181) measurements were put on ice
immediately after collection and separated by centrifugation for 15 min at
3000 rpm. Plasma samples were subsequently stored in aliquots at20
to80 C pending further analysis. FGF21 levels were measured using a
commercially available enzyme-linked immunosorbent assay (ELISA)
(Eagle Biosciences, F2131-K01) that detects full-length, active FGF21 (1e
181), but not FGF21 fragments generated via recently described cleavage
events at the N-terminus by dipeptidyl peptidase 4 (DPP-4), or at the C-
terminus by ﬁbroblast activation protein (FAP) that could lead to over-
estimates of the amount of FGF21 in circulation [17e19]. The standard
curve range for the assay is 32.5e2000 pg/ml, with a LoD of 1.7 pg/ml.
FGF21 was assayed in duplicate and calculated using the mean of rep-
licates. Total FGF21 was also measured in duplicate using a kit that de-
tects total FGF21 (R&D Systems, DF2100). The LoD for this assay is
4.67 pg/ml and a standard curve ranging from 31.3 to 2000 pg/ml.
2.7. General hormone analyses
All subjects in the acute alcohol study attended a pre-examination day
with routine blood samples to screen for diseases before they were
included in the experiment. Measurements of hemoglobin and glycosy-
lated hemoglobin (Hb1Ac) and plasma levels of insulin, C-peptide,
glucose, cholesterol, triglycerides, ALAT, ASAT, thyroid hormones,
thyrotropin, alkaline phosphatase, carbamide, and urea were performed
using standard techniques at the Department of Clinical Biochemistry,
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark or at
the Department of Clinical Biochemistry, Gentofte Hospital, University of
Copenhagen, Hellerup, Denmark. Blood samples for insulin, C-peptide,
and glucose were immediately spun at 4 C at 3000 rpm for 15 min, and
were stored at 2e4 C until analysis the same day. Plasma insulin was
analyzed by electrochemiluminescent immunoassay (Cobas, Roche) and
C-peptide by sandwich electrochemiluminesence-immunoassay (ECLIA).
2.8. Mouse alcohol preference test
Eighteen male C57BL/6 N mice (8e10 weeks old; Taconic, Denmark)
were singly housed and given the choice between water and a 4%
ethanol solution. Every day, the consumption of both was determined
by weighing the drinking bottles. A stable, 4-day, pre-treatment
baseline intake was established for each mouse. Every other day,
the position of the two drinking bottles was reversed to ensure that
there was no side-preference bias for any of the mice. Half of the mice
were treated with FGF21, through intraperitoneal injection with a so-
lution of FGF21 (10 mg/ml in PBS, a 1 mg/kg dose) for 3 days. The
other half received injections of PBS during the same period.
2.9. Statistical analysis
All analyses were performed using the Statistical Package for SAS 9.1
(SAS Institute, Cary NC, USA) or GraphPad Prism v6.0 (GraphPad98 MOLECULAR METABOLISM 11 (2018) 96e103  2018 The Authors. Published by Elsevier GmbH.Software, La Jolla, CA). Data are presented as mean and standard
deviations for normally distributed variables. Relevant statistical test,
sample size, and signiﬁcance level for each analysis are stated in
ﬁgure legends. p-values below 0.05 where Benjamani-Hochberg
Q < 0.05dif relevant due to multiple comparisondwere consid-
ered statistically signiﬁcant.
3. RESULTS
3.1. Alcohol ingestion acutely increased levels of total and active
FGF21 (1e181) in human plasma
Ten healthy, fasted male subjects were randomly assigned to groups
similar in anthropometric and metabolic variables at baseline (Table 1).
After an overnight fast and basal blood sampling, all participants
received a single oral bolus of either water or alcohol, and blood
samples were collected for the next four hours while participants did
not eat or drink, since nutrients inﬂuence hepatic FGF21 production in
a complex manner [20,21].
After drinking water or 8 cL 40% alcohol (25.3 g pure ethanol) diluted
in water to an equal total volume, blood alcohol level (BAC) increased
only in the alcohol group as anticipated, rising to a peak of 0.043% at
30 min, and returning to zero after three hours (Supplementary
Table 1). Because increases in blood glucose can elevate circulating
FGF21 levels [22], we also measured plasma glucose, insulin and C-
peptide during the experiment. Although differences in insulin or C-
peptide were not observed between groups, their absolute levels
decreased over time, consistent with the increased period of fasting.
However, plasma glucose levels were signiﬁcantly lower in the alcohol
group after 90 min, and remained lower for the duration of the
experiment (Supplementary Table 1).
In baseline samples (t ¼ 0) from these subjects, we observed sub-
stantial variation (9e490 pg/ml) in FGF21 (1e181) between in-
dividuals, irrespective of group (Table 1). Accordingly, FGF21 results
are expressed as fold-changes from baseline for each subject, to
express treatment effects. As expected, ingestion of water did not lead
to a change in levels of active FGF21 (1e181) at any time point,
whereas ingestion of alcohol resulted in a 2.3-fold increase in circu-
lating FGF21 (1e181) levels after 90 min, with a peak 3.4-fold overThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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baseline at 120 min (Figure 1A). We measured FGF21 (1e181) instead
of total FGF21 because of recent reports that FGF21 (1e181) is
truncated at the N-terminus by DPP-4, and at the C-terminus by FAP,
abrogating its ability to signal [17e19,23,24]. Therefore, total FGF21
reagents may give inﬂated estimates of FGF21 levels as they measure
the sum of FGF21 (1e181) and derived inactive fragments [25].
Consistent with this possibility, total within-subject FGF21 levels
increased an average of 10-fold from baseline (range: 6e163 pg/ml)
to 120 min (range: 90e532 pg/ml) in the alcohol group, versus 3.4-
fold for FGF21 (1e181) (Figure 1B).
Next, to determine whether alcohol is a potent inducer of FGF21
secretion relative to other sources of energy, we measured total FGF21
levels at baseline and after 120 min in subjects given 75 g of oral
sucrose in water [15]. In this case, total FGF21 levels increased 1.9-
fold at 120 min (also the peak time for sucrose), far less than the
apparent 10-fold increase observed with alcohol using the total re-
agent, despite the fact that 25.3 g of ethanol contains 113 fewer kcal
than 75 g of sucrose (Figure 1C).
3.2. Bolus treatment with recombinant human FGF21 reduced
alcohol intake in mice
We subsequently investigated the potential physiological role of this
transient increase in FGF21 after acute alcohol ingestion in mice. After
a four-day baseline period with unrestricted, simultaneous access to
water and a 4% ethanol solution, mice were injected with recombinant
human FGF21 or vehicle once per day, and their ad libitum alcohol and
water intake was compared to their baseline intake. This design was
used to mitigate inter-individual differences caused by variable but
stable preferences for a speciﬁc ratio of water to alcohol consumed byFigure 1: A) Relative fold change in active plasma FGF21 (1e181) in humans after drinki
levels at t ¼ 0 for each subject. B) Relative fold change in total plasma FGF21 in the sam
Benjamani-Hochberg Q < 0.05. C) Effect of 75 g oral sucrose on total FGF21 plasma levels
by paired, two-tailed Student’s t-test. D) Effect of intraperitoneal FGF21 administration (1 m
and three days of FGF21 treatment (n ¼ 8e9/group), * Denotes p < 0.015 by paired, tw
MOLECULAR METABOLISM 11 (2018) 96e103  2018 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comeach mouse. In agreement with similar reports using infusion mini-
pumps, FGF21-treated mice drank 21% less 4% alcohol solution
relative to their own, untreated baseline (Figure 1D), and this decrease
was statistically signiﬁcant (p ¼ 0.015). By contrast, vehicle control-
treated mice consumed the same amount of the 4% alcohol solution
during treatment relative to baseline (2.2  0.8 (SEM) ml/day at
baseline vs. 1.94  0.7 ml/day with vehicle treatment, n ¼ 9,
p ¼ 0.12). In addition, water intake was similar before and after
treatment with vehicle (2.6  0.8 ml/day pre vs. 2.4  0.6 ml/day
post, n ¼ 9, p ¼ 0.54), or FGF21 (2.2  0.8 ml/day pre vs.
2.5  0.8 ml/day post, n ¼ 8, p ¼ 0.39).
3.3. Oktoberfest binge drinking increased FGF21 (1e181), and
total FGF21, but produced relatively minor changes in hepatic and
metabolic markers
At the festival, the three subjects consumed an average of 22.6 beers/
person/day (4.4 g/kg/day pure ethanol or 7.46 Lbeer/person/day)
(range: 16e28 beers/day) for three days (Figure 2A). Remarkably, the
three-day period of concerted drinking elicited relatively minor
changes in blood chemistry, and no changes in liver stiffness and
triglyceride content assessed by ﬁbroscan. As expected, plasma levels
of ASAT, a marker of hepatic injury, increased by an average of 25%
relative to baseline measurement, but remained within the normal
clinical range. Another circulating marker of hepatocyte lysis, ALAT,
tended to increase to a similar extent, but also remained within normal
clinical limits (Supplementary Table 2). With respect to metabolic
parameters, fasting plasma glucose was higher in all subjects after
the return from the Oktoberfest compared to baseline, but was
not accompanied by changes in insulin, C-peptide, HOMA-IR, orng water or ethanol in water (z2 standard US drinks/3 UK units), normalized to FGF21
e samples from A (n ¼ 5/group), * denotes statistical signiﬁcance (p < 0.05) where
in healthy volunteers, using the same reagent as in B (n¼ 40), ****Denotes p < 0.0001
g/kg) on average daily intake of a 4% ethanol solution in mice over four days of baseline
o-tailed Student’s t-test.
ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 99
Figure 2: A) Individual-level beer consumption at Oktoberfest 2017 by festival day. B) Active plasma FGF21 (1e181) levels before and after consuming an average of 22.6 beers/
day for three days. C) Change in total plasma FGF21 levels before and after 3 days at Oktoberfest and three weeks of follow-up (n ¼ 3/group), * Denotes statistical signiﬁcance,
p < 0.05 by paired, two-tailed Student’s t-test. D) Correlation between changes in total plasma FGF21 and the liver enzyme aspartate transaminase (ASAT) after Oktoberfest and
follow-up (r2 ¼ 0.93, p < 0.002).
Original ArticleHOMA-2-IR. However, plasma triglyceride increased by an average
of 161% following Oktoberfest exceeding the normal clinical range in
all three subjects (Supplementary Table 2). Similarly, plasma FGF21
(1e181) was elevated by an average of 110% upon return (Figure 2B),
and total plasma FGF21, including cleavage products, was increased
90% (Supplementary Table 2).
Although within-subject plasma FGF21 levels are stable over time
[24,26,27] we evaluated the possibility that FGF21 could have
increased stochastically during Oktoberfest by repeating the FGF21
measurement and blood chemistries for a third time, three weeks after
the initial return visit. Consistent with our hypothesis, three weeks after
resuming a normal lifestyle, total circulating FGF21 returned to near
pre-Oktoberfest baseline levels in all subjects (Figure 2C). Interestingly,
the changes in FGF21 during and after Oktoberfest mirrored changes in
the liver enzyme ASAT, highlighting a potential relationship between
hepatic stress in humans and increased basal FGF21 production
(Figure 2D). Nevertheless, the strength of the correlation varied be-
tween subjects, suggesting that FGF21 secretion is not strictly coupled
to hepatocyte death, in keeping with its putative role as a signaling
molecule.100 MOLECULAR METABOLISM 11 (2018) 96e103  2018 The Authors. Published by Elsevier GmbH.Next, we investigated whether increased intake of fructose, or major
changes in food intake, could contribute to the increased post-
Oktoberfest FGF21 levels by examining the food diaries provided by
each subject. This revealed that none of the subjects exhibited aberrant
patterns of food intake, or had consumed signiﬁcant amounts of sugar-
rich foods (Supplementary Table 3). In fact, subjects skipped meals
frequently, likely as a consequence of consuming roughly 3,800 kcal/
day each in beer.
3.4. Basal levels of active FGF21 (1e181) in human plasma were
not associated with alcohol-related behavior or problems in non-
alcoholic humans
Together, our results in humans and mice suggest that FGF21 (1e181)
may increase after alcohol drinking to discourage further alcohol
consumption. Therefore, we investigated whether FGF21 (1e181)
levels are correlated with alcohol drinking patterns or problems in
humans. Subjects from the alcohol challenge study described above
(n ¼ 10), as well as participants from a previous study by our group
that investigated FGF21 and sweet preference (n ¼ 39) (average
fasting FGF21 (1e181) for the latter cohort: 66.8  59.6 (SD) pg/ml),This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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completed two alcohol use questionnaires: AUDIT and Alcohol E (see
Materials and Methods for details). Because the two cohorts were
similar in demographic and anthropometric characteristics
(Supplementary Table 4), their responses were pooled for analysis. For
each survey question and the AUDIT total questionnaire score, we
calculated a Spearman correlation coefﬁcient (r) with fasted levels of
active plasma FGF21 (1e181). However, we did not observe a sig-
niﬁcant relationship between FGF21 levels at baseline and any alcohol-
related behaviors, emotional responses, or problems in either AUDIT or
Alcohol E in this small cohort (p > 0.05 for all correlations)
(Supplementary Figure 1 and Supplementary Table 5).
4. DISCUSSION
Here we show, in humans, that FGF21 (1e181) levels in circulation are
increased more than 3-fold by acute alcohol intake and that sub-
chronic alcohol binge drinking in a natural setting (Oktoberfest 2017,
Munich) persistently increases FGF21 levels, which subsequently re-
turn to normal three weeks later. Further, we show that once-daily
bolus injection of recombinant human FGF21, in mice, is sufﬁcient
to reduce ad libitum alcohol intake by 21%.
Our ﬁndings are consistent with the negative-feedback hypothesis of
Schumann et al. who associated variants in KLB with alcohol intake in
humans, and further demonstrated that continuous FGF21 infusion by
minipump reduces alcohol intake through b-klotho in the central
nervous system [4]. Here we provide evidence in line their prediction
that the human liver secretes FGF21 in response to alcohol intake.
Our work is also strongly supportive of a recent report by Desai and
coworkers that alcohol acutely increases total circulating FGF21 in
humans [16]. While we observed a smaller increase in circulating
FGF21 (1e181) after alcohol ingestion when compared to their 0.9 g/
kg dose (3.4-fold vs 40-fold), the explanation for this appears to be a
non-linear relationship between FGF21 secretion and increasing
doses of alcohol, as well as the FGF21 assay employed. The alcohol
dose we used was slightly lower than the lowest 0.4 g/kg dose in
their study, which evoked less FGF21 secretion than the 0.9 g/kg
dose (10-fold vs. 40-fold). In agreement with Desai et al. we also
observed a 10-fold peak increase in total FGF21 with acute alcohol
when using the same ELISA kit. Thus, alcohol bingeing (e.g. 0.9 g/kg)
may elicit exaggerated FGF21 secretion relative to moderate drinking,
which could be relevant to the pathogenesis of alcohol abuse if
FGF21 has reinforcing, in addition to acute anti-consumptive, effects
in the central nervous system. In addition, because alcohol appears to
be the strongest physiological inducer of FGF21 identiﬁed to date in
humans [16], it will be of interest to uncover the mechanism
responsible for alcohol-mediated FGF21 secretion, as it may offer
new targets for stimulating FGF21 production to achieve therapeutic
ends.
A potential contributor to the temporal difference in FGF21 secretion
between our study and that of Desai et al. is the fact that subjects in
their ﬁrst study had access to food, which may have complex effects
on FGF21 production in humans, whereas our subjects were fasted
[20,28,29]. However, subjects in their second study were given 0.9 g/
kg alcohol six hours before their ﬁrst meal, and still exhibited a secular
increase in total plasma FGF21 after two hours, indicating that the
higher ethanol dose in Desai likely explains most of the temporal
differences in FGF21 secretion between our studies [16]. A further
salient difference between our acute studies was one of the ELISA
assay kits used; Desai et al. measured total FGF21 whereas we
measured active, full-length FGF21 and total FGF21 in our acute study.
We focused on active FGF21 in light of recent reports that FGF21MOLECULAR METABOLISM 11 (2018) 96e103  2018 The Authors. Published by Elsevier GmbH. This is an open a
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and that C-terminally intact FGF21 is highly correlated with total FGF21
when total FGF21 is measured with a capture antibody targeted to
avoid regions subject to proteolysis [30]. Therefore, total FGF21 re-
agents may also measure inactive FGF21 fragments. This supposition
is supported by our additional observation that the fold change in total
FGF21 evoked by alcohol follows the same temporal pattern but is 3
times greater than that in FGF21 (1e181) in the same samples.
However, future quantitative LC/MS/MS-based studies are needed to
distinguish this possibility from other ELISA-speciﬁc artefacts (e.g.
differences in sensitivity) that may cause differences in FGF21 fold-
change estimates. Nevertheless, it is evident from the existing data
that both acute and subchronic alcohol exposure increase total FGF21
and FGF21 (1e181) levels in humans.
FGF21 overexpression or continuous infusion by minipump decreases
alcohol intake in mice [4,13]. However, it was not clear whether bolus
injection of FGF21, whose t1/2 is approximately 1e2 h [31], would have
long-lasting effects on alcohol intake. Because FGF21 (1e181) peaks
and declines rapidly after alcohol drinking, and because we previously
observed a durable effect of bolus FGF21 administration on sweet
appetite [32], and suspect that this ability to reduce sweet and alcohol
intake may be mediated by a partially overlapping population of b-
klotho positive neurons, we hypothesized that bolus injection of FGF21
(1e181) would also reduce alcohol intake over a 24 h period.
Consistent with this, human FGF21 administered once every 24 h was
sufﬁcient to reduce overall alcohol intake by 21% in mice. This sug-
gests that transient increases in FGF21 may have persistent effects on
drinking behavior.
Our results are reminiscent of prior reports that oral boluses of fructose
[21], sucrose [15], and glucose [22] acutely increase circulating FGF21
levels in humans and rodents. In these cases, the change in FGF21
secretion is smaller and may be a physiological, negative-feedback
mechanism to inhibit sweet intake; Fgf21 knockout mice consume
twice as much sucrose as wild type [32], FGF21 (or FGF21 analog)
injection reduces sweet intake in mice and non-human primates
[13,32], and the rs838133 A-allele in the Fgf21 gene is associated
with increased sweet snacking in humans [15]. These studies provide
evidence that FGF21 reduces sweet intake in a physiological context.
Given our current data, we posit that there may be an overlapping
circuit regulating alcohol intake that also relies on FGF21. Indeed, we
previously reported that the FGF21 rs838133 A-allele is associated
with increased alcohol consumption in the Danish Inter99 cohort
(n¼ 6,514) [15]. However, in contrast to sugars, Fgf21 knockout mice
do not consume more alcohol than wild type, leaving the physiological
role of FGF21 in regulating alcohol intake in doubt [16]. One possible
explanation for this is compensatory signaling via FGF15/19, though
this remains speculative.
Intriguingly, although pharmacological FGF21 treatment reduces body
weight and food intake in primates [20], the sweet-increasing Fgf21
rs838133 A-allele is linked to slightly lower BMI in humans. This is at
odds with the concept that FGF21 regulates body weight by limiting
sweet and alcohol intake [15]. An alternative hypothesis is that a
negative-feedback axis between the liver and brain evolved to limit
overindulgence in fructose and alcohol from fermented fruits and
nectars, as this can be hepatotoxic. For example, the pen-tailed
treeshrew (Ptilocerus lowii), a mammal similar to an extinct primate
ancestor of modern humans, consumes large amounts of fermented
nectar from the bertam palm (Eugeissona tristis), which has alcohol
content similar to beer. Thus, human ancestors may have experienced
pressure to balance the value of alcohol as an energy source with its
deleterious effects on liver when consumed in excess [33]. The abilityccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 101
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of such an adaptation [8]. Another possibility is that the induction of
FGF21 by dietary sugars and alcohol may promote balanced food
selection, in particular protein intake. Indeed, FGF21 is strongly
upregulated by protein restriction [34,35], suggesting that limiting the
drive to consume foods that are calorie-rich but protein poor may be
adaptive after a certain threshold of intake.
Our ﬁnding that three days of heavy drinking at Oktoberfest increased
fasting plasma FGF21 (1e181) levels by 110% after 32 h of alcohol
abstinence raises the possibility that FGF21 may regulate alcohol
intake in both sub-chronic and acute contexts. However, the increase
in FGF21 after Oktoberfest may also be a response to increased car-
bohydrate intake and hepatic lipid content derived from excess food
consumption, which has previously been demonstrated in humans,
and is also consistent with the large increases in circulating triglyceride
observed in these subjects [28]. Therefore, further studies will be
required to deﬁnitively establish a direct link between increased sub-
chronic levels of alcohol intake and changes in circulating FGF21 in
humans, although the subjects in the Oktoberfest cohort did appear to
eat relatively normally. In addition, it is notable that FGF21 is increased
dramatically (roughly 10-fold more) relative to canonical liver enzymes
(e.g. ASAT and ALAT) by binge drinking, suggesting that it may be a
promising biomarker for recent alcohol abuse. Finally, while one might
conclude that the FGF21 induction caused by acute alcohol intake
reﬂects transient hepatic stress, recalling that FGF21 secretion is also
elevated in mitochondrial myopathies [36], in fact the hepatotoxin
acetaminophen decreases circulating FGF21 levels [37], more
consistent with the idea that acute FGF21 secretion may be selectively
regulated by alcohol ingestion to fulﬁll a signaling function (e.g.
stimulate fatty acid oxidation or promote alcohol satiation/satiety).
Notably, however, the changes in total plasma FGF21 levels after
Oktoberfest and over the three week follow-up period were highly
correlated with increases, and then decreases, in the hepatocyte-
derived enzyme ASAT. This suggests that the sub-chronic increase
in plasma FGF21 after an alcohol binge may indeed be related to liver
injury. Therefore, there may be at least two temporally distinct modes
by which FGF21 regulates alcohol intake; acutely with no changes in
liver enzymes [38], and prolonged where ongoing hepatic stress ele-
vates basal FGF21 release and secretion in response to physiological
elicitors. Supporting this concept, obese individualsdlikely with fatty
liverdexhibit an exaggerated FGF21 secretory response to ingested
fructose [21].
Given the genetic link between FGF21 and alcohol intake in humans, it
is notable that we did not ﬁnd a correlation between fasting FGF21 (1e
181) levels in plasma and alcohol-related behavior, emotional re-
sponses, and problems as measured by the AUDIT and ALCOHOL-E
questionnaires. Potential explanations for this are the fact that our
sample size was small, and did not include subjects with abnormal
drinking behavior. Otherwise, the association between KLB variants
and alcohol intake may be mediated by FGF19, which emanates from
the gastrointestinal tract and can also signal via the FGFR1/b-klotho
receptor in the brain, in addition to the FGFR4/b-klotho complex in the
liver to regulate bile acid production [39]. Future studies will be
required to distinguish between these alternatives.
In conclusion, the present work supports the hypothesis that circu-
lating FGF21 may be a liver-derived inhibitor of alcohol intake in
humans, akin to gut peptides that reduce food intake after meals.
However, further work is required to establish this via clinical trials and
to understand whether hepatic hormones play a more general role than
anticipated in regulating ingestive behavior, given the importance of
the liver as a metabolic integrator.102 MOLECULAR METABOLISM 11 (2018) 96e103  2018 The Authors. Published by Elsevier GmbH.ACKNOWLEDGEMENTS
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